TGF-β2 Reduces the Cell-Mediated Immunogenicity of Equine MHC-Mismatched Bone Marrow-Derived Mesenchymal Stem Cells Without Altering Immunomodulatory Properties

TGF-β2 Reduces the Cell-Mediated Immunogenicity of Equine MHC-Mismatched Bone Marrow-Derived Mesenchymal Stem Cells Without Altering Immunomodulatory Properties

Allogeneic mesenchymal stem cells (MSCs) are a promising cell therapy for treating numerous diseases, but major histocompatibility complex (MHC)-mismatched MSCs can be rejected by the recipient’s immune system. Pre-treating MSCs with transforming growth factor-β2 (TGF-β2) to downregulate surface exp...

Full description

Bibliographic Details
Main Authors: Alix K. Berglund, Julie M. Long, James B. Robertson, Lauren V. Schnabel
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Cell and Developmental Biology
Subjects:
mesenchymal stem cell
TGF-β2
cytotoxicity
immunogenicity
major histocompatibility complex
allogeneic
Online Access:https://www.frontiersin.org/articles/10.3389/fcell.2021.628382/full

Internet

https://www.frontiersin.org/articles/10.3389/fcell.2021.628382/full

Similar Items